Changes in T-cell subpopulations and cytokine network during early period of ibrutinib therapy in chronic lymphocytic leukemia patients: the significant decrease in T regulatory cells number
Monika Podhorecka(Medical University of Lublin), Marek Hus(Medical University of Lublin), Olga Jankowska‐Łęcka(Medical University of Lublin), Arkadiusz Macheta(Medical University of Lublin), Dariusz Jawniak, Aneta Gorący(Medical University of Lublin), Blanca Gil Ibáñez(Medical University of Lublin), Aleksandra Nowaczyńska(Medical University of Lublin), Sylwia Chocholska(Medical University of Lublin), Agnieszka Szymczyk(Medical University of Lublin), Małgorzata Kowal(Medical University of Lublin), Elzbieta Drab-Urbanek(Medical University of Lublin)
Cited by 34
Related Papers
Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
|New England Journal of Medicine|2024|162
Therapy‐related peripheral neuropathy in multiple myeloma patients
|Hematological Oncology|2014|70